HYPE: Tranexamic acid serum fades melasma and dark spots.
But what does the evidence actually show?
Topical tranexamic acid has supportive human trials for melasma, usually over weeks to months. Benefits vary by formulation, and evidence for a topical serum should be separated from oral treatment and from every other cause of pigmentation.
What is the hype?
Tranexamic acid is associated with pathways involved in pigment production, making it a plausible option for uneven pigmentation. The strongest practical question is whether a particular topical formula improves diagnosed melasma compared with a suitable control, rather than whether the ingredient name appears in any successful treatment.
The wider review mixes treatment routes
A systematic review of 22 trials involving 1,280 patients found improvements in melasma with tranexamic acid. However, it combined oral, topical and injected treatment evidence, with substantial variation between studies. Oral-treatment findings cannot be used as the expected effect of a cosmetic serum. Route-specific trials are more useful for this question. [1]
A topical comparison found similar average improvements
A 12-week randomised study analysed 100 patients receiving topical tranexamic acid 5% or hydroquinone 3%. Melasma-severity scores fell by about 27% in both groups, without a statistically significant between-group difference. This supports potential usefulness, but a non-significant difference does not by itself prove formal equivalence. It was also a comparison with active treatment rather than a plain vehicle. [2]
Another formulation illustrates the uncertainty
A split-face study enrolled 30 women, with 23 completing 12 weeks of liposomal tranexamic acid 5% on one side and hydroquinone 4% on the other. Both sides improved; the between-treatment difference was not statistically significant. Liposomal delivery is part of the tested product, so the result cannot isolate the ingredient from its formulation. [3]
Melasma is not a label for every dark mark
A pigmentation score in melasma does not establish treatment of all sun spots, acne marks or new pigmented lesions. Baseline diagnosis, skin type, accompanying sun protection and other treatment affect interpretation. A serum promising universal spot removal is making a broader claim than these clinical comparisons tested.
The catch: limitations and uncertainty
Trials are often small, short and use different concentrations, bases and outcome scales. Active-comparator designs do not always reveal the effect beyond a moisturising vehicle. Longer follow-up is needed for durability and relapse, and small samples provide limited information on uncommon adverse effects.
What this means for you
Consider a topical product as one possible part of an appropriate melasma plan, with realistic expectations and sun protection. Introduce it cautiously if your skin is reactive. Do not convert serum research into a reason to take oral tranexamic acid: oral treatment has a different risk assessment and requires clinical advice. New or changing pigmented lesions need assessment rather than cosmetic experimentation.
A credible melasma ingredient, with formulation and diagnosis still central to the result.
Research & Sources
1. Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials (2024).
Published abstract; mixed treatment routes.
Read the original source ↗2. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma (2019).
Published abstract; 100 analysed participants.
Read the original source ↗3. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma (2015).
Published abstract; small split-face trial.
Read the original source ↗Evidence reviewed: October 2026
This targeted editorial review considered sources available in October 2026. It is not an exhaustive systematic review. Source access and indirect evidence are identified above. Evidence vs Hype provides education, not individual diagnosis or treatment. Original AI-generated featured artwork is conceptual and does not demonstrate a study result. No commercial product was selected or endorsed.